Angela Caglia Skincare introduces patented human stem cell tech
Angela Caglia, Master Esthetician and skin care formulator, has debuted her self-named skin care brand's Cellular Collection, which leverages human mesenchymal stem cells (MSCs) byproducts in skin care. The first product in this line, Cell Forté Serum, utilizes the world's first patented human-derived stem cell technology byproduct, according to Caglia, marking a significant innovation in non-invasive anti-aging solutions.
Caglia’s formulation approach could have far-reaching implications for the cosmetics and personal care industry as the demand for advanced, science-backed skin care products continues to grow, and we spoke to her to learn more about the science behind the product launch.
Stem cell technology in skin care
The core innovation of Cell Forté Serum lies in its use of byproducts from MSCs, which were originally studied for their healing properties in treating conditions such as dementia, Parkinson’s disease, and arthritis. Now, these same regenerative capabilities are being applied to skin care.
“MSC’s contain healing properties that help prevent UV-induced skin damage and promote cell regeneration,” Caglia explained. However, she clarified that the actual stem cells are not present in the formulation. “There are no MSCs in our skin care," she said, as "the stem cells wouldn’t survive in the jar nor penetrate the skin due to their molecular size."
Instead, she shared, "we use the byproduct of MSCs, duplicated and created under sterile cGMP-certified lab conditions.” This distinction emphasizes the role of exosomes, growth factors, and cytokines derived from MSCs as the active components driving skin regeneration in the serum.
Importantly, the serum is DNA-free and works without disrupting the skin’s natural barrier, a common issue with many anti-aging products currently on the market.
Benefits for skin health and anti-aging
MSC byproducts stand out for their natural wound-healing abilities, making them highly effective for skin rejuvenation. "Mesenchymal stem cells are the superhero of the body when it comes to wound healing,” said Caglia. “When we are young, MSCs regenerate our cells so wounds heal faster."
However, she continued, "as we get older, these stem cells decline, and that’s where we come in.” By utilizing the bioproducts of MSCs rather than the stem cells themselves, Caglia’s serum takes advantage of the regenerative properties without requiring the invasive methods traditionally associated with stem cell therapies.
She also clarified that while stem cells do require regulatory approval when injected, the product line is not "doing that with stem cells—that would be a drug." Instead, "we are a cosmetic and DNA-free, utilizing the byproduct from a clinical research lab that is mainly used for clinical trials and medical research." This ensures that the product complies with both cosmetic and ethical standards.
By harnessing ethically sourced, patented protein-rich human stem cell-conditioned media, Cell Forté Serum is formulated to help regenerate the skin’s barrier, stimulate collagen synthesis, and reduce the appearance of fine lines, wrinkles, and hyperpigmentation. Caglia claims that within four weeks of consistent use, users can see significant improvements in skin brightness and radiance.
Market implications, consumer demand, and ethical considerations
For cosmetics and personal care manufacturers and suppliers, the introduction of MSC byproduct technology into skin care products represents a new frontier in product innovation. Caglia’s serum not only taps into the growing consumer interest in non-invasive anti-aging treatments but also aligns with the rising demand for ethically sourced, science-backed ingredients.
The clinical benefits of MSC byproducts, including their role in skin regeneration and UV protection, provide a compelling value proposition for manufacturers looking to incorporate cutting-edge technology into their product lines. With its focus on real, patented human stem cell byproduct technology, Cell Forté Serum differentiates itself from competitors that rely on synthetic or plant-based alternatives.
This technological innovation, combined with the product’s ability to stimulate the skin’s natural healing process, could signal a shift in the market toward more advanced, regenerative skin care solutions.
Caglia has also prioritized ethical sourcing and clinical validation throughout the product’s development. The MSCs used in Cell Forté Serum are obtained from consenting, healthy adults, and the protein-rich media is processed in a certified medical research lab.
This ensures that the product adheres to both ethical and scientific standards, offering transparency and credibility to both suppliers and consumers.
Future outlook
With the launch of the Cell Forté Serum as the cornerstone of her Cellular Collection, Caglia is positioning her brand at the intersection of luxury and science. As more consumers seek out effective, non-invasive solutions to skin aging, human stem cell technology byproducts could become an increasingly important tool in the skin care industry. For manufacturers and suppliers, the success of this patented technology may open the door to further innovations and expanded product lines.
Caglia has hinted at additional product releases within the Cellular Collection, expected to roll out in 2025, which could further solidify her brand's reputation as a leader in regenerative skin care. As demand for scientifically backed, results-driven skin care products grows, Caglia’s stem-cell byproduct technology offers a compelling option for companies looking to stay at the forefront of the industry.
